Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2024

Pharma News, 2024

Amplia Therapeutics’ Narmafotinib Gets Fast-track Designation from FDA
Amplia Therapeutics’ Narmafotinib Gets Fast-track Designation from FDA
The US Food and Drug Administration (FDA) has granted fast-track designation to narmafotinib, Amplia Therapeutics’ lead drug for the treatment of advanced pancreatic cancer. In the future, n...
Gene Therapy Restores Vision
Gene Therapy Restores Vision
A new gene therapy ATSN-101 has restored vision in patients with Leber congenital amaurosis type I (LCA1), a rare genetic condition causing blindness. In a small trial, those receiving the hig...
GSK hails positive results of Nucala clinical trials in lung disease
GSK hails positive results of Nucala clinical trials in lung disease
GSK PLC on Friday announced positive headline results of the Matinee phase III clinical trial evaluating Nucala.
FDA approves Amneal and Shilpa’s oncology product BORUZU
FDA approves Amneal and Shilpa’s oncology product BORUZU
The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals and Shilpa Medicare’s oncology product BORUZU for subcutaneous administration. BORUZU, the first ready-to-use ve...
Lilly partners with Haya for lncRNA obesity target deal worth $1bn
Lilly partners with Haya for lncRNA obesity target deal worth $1bn
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Haya could secure up...
FDA Grants Orphan Drug Designation to Certepetide in Cholangiocarcinoma
FDA Grants Orphan Drug Designation to Certepetide in Cholangiocarcinoma
The FDA has granted an orphan drug designation (ODD) to the investigational agent certepetide (formerly LSTA1) for the treatment of cholangiocarcinoma, according to an announcement fro...
Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference
Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference
Sensei Biotherapeutics, Inc., a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical da...
New Prostate Cancer Treatment Shows Promise in Preclinical Studies
New Prostate Cancer Treatment Shows Promise in Preclinical Studies
Data from a team of Australian researchers shows the potential of a new therapeutic strategy for treating castration-resistant prostate cancer (CRPC), the most aggressive form of the disease. ...
Actimed’s ALS candidate wins FDA orphan drug designation
Actimed’s ALS candidate wins FDA orphan drug designation
Actimed’s ALS candidate wins FDA orphan drug designation
FDA approves Azurity’s Nymalize oral solution in prefilled syringe
FDA approves Azurity’s Nymalize oral solution in prefilled syringe
Azurity Pharmaceuticals’ Nymalize (nimodipine) oral solution in a 30mg/5ml prefilled ENFit syringe has received US Food and Drug Administration (FDA) approval.
Pfizer on Opposite Sides of Two Promising Vaccine Trials
Pfizer on Opposite Sides of Two Promising Vaccine Trials
Data from two promising vaccine trials, announced Tuesday, heralded potential breakthroughs in the treatment of pneumococcal infection and Lyme disease. One could add to pharma giant Pfizer’s market...
Dr. Reddy's banned from China's drug procurement program after inspectors turn up manufacturing problems
Dr. Reddy's banned from China's drug procurement program after inspectors turn up manufacturing problems
Dr. Reddy’s has been cut off from China’s bulk-buy drug procurement program after an inspection turned up “serious defects” in the company’s manufacturing operations. Following a remote insp...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand